Tool
Supplement comparison tool
Pick up to 4 knowledge base entries and compare their dosage, price, evidence strength and ratings side by side — you can save or share a link to your selection.
Add to comparison (2/4)
| Category | Leki | Leki |
| Evidence strength | Strong evidence | Strong evidence |
| Evidence Score | 4/5 | 5/5 |
| User rating | 4.5 (83) | 4.5 (58) |
| Typical dose | Esketamine (Spravato): starting dose of 56 mg intranasally on day 1, then 56 or 84 mg twice weekly for the first 4 weeks, later once weekly or every 2 weeks during the maintenance phase, always combined with an oral antidepressant. Off-label IV ketamine: typically 0.5 mg/kg body weight over a 40-minute infusion, given as a series of several sessions (e.g. 6 sessions over 2-3 weeks) in a clinical setting. | Start at 2.5 mg weekly, gradual escalation every 4 weeks to a maintenance dose of 5, 7.5, 10, 12.5, or a maximum of 15 mg weekly, depending on tolerance and treatment goal |
| Form | Spravato — an intranasal spray containing esketamine, a prescription drug. Off-label IV ketamine — an infusion given exclusively in clinical settings by medical staff. | Solution for subcutaneous injection in a single-use autoinjector (Mounjaro, Zepbound) |
| Average price | Jedna sesja dożylnego wlewu ketaminy w prywatnej klinice w Polsce: ok. 800–2000 zł; esketamina (Spravato) w ramach prywatnej opieki psychiatrycznej bywa droższa ze względu na koszt samego leku i wymóg certyfikowanej placówki | ok. 1000–1600 zł za opakowanie miesięczne, zależnie od dawki i apteki |
| Monthly cost | W fazie indukcyjnej (2 podania tygodniowo) koszt miesięczny może sięgać kilku tysięcy złotych, zależnie od placówki i formy leczenia | ok. 1000–1600 zł/miesiąc |
| Time to effects | The antidepressant effect can be noticeable within hours to 24 hours after the first administration, though in most patients it's short-lived after a single dose and requires a series of repeated administrations within a supervised protocol to maintain the effect during the maintenance phase. | Reduced appetite is sometimes noticeable within the first few weeks, but meaningful, measurable weight loss develops gradually over several months, and the full effect assessed in SURMOUNT-1 was measured after 72 weeks (about 1.5 years) of regular treatment. |
| Who it's for | Patients with a formal diagnosis of treatment-resistant depression who have not responded to at least two prior lines of standard pharmacological treatment | People with type 2 diabetes with inadequate glycemic control on other oral medications |